Aripiprazole
- Generic Name
- Aripiprazole
- Brand Names
- Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27Cl2N3O2
- CAS Number
- 129722-12-9
- Unique Ingredient Identifier
- 82VFR53I78
- Background
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A ...
- Indication
Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation as...
- Associated Conditions
- Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
- Associated Therapies
- Monotherapy
A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2020-09-02
- Target Recruit Count
- 72
- Registration Number
- NCT03854409
- Locations
- 🇺🇸
Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
🇺🇸Community Clinical Research, Austin, Texas, United States
Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals
- Conditions
- Interventions
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 2700
- Registration Number
- NCT03790085
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, China
Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2021-03-09
- Target Recruit Count
- 36
- Registration Number
- NCT03661983
- Locations
- 🇺🇸
Reliable Clinical Research, Hialeah, Florida, United States
🇺🇸Pediatric and Adolescent Neurodevelopment Associates, Atlanta, Georgia, United States
🇺🇸Alivation, Lincoln, Nebraska, United States
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2020-07-16
- Target Recruit Count
- 44
- Registration Number
- NCT03568500
- Locations
- 🇬🇧
Clinical Trial Site, Southampton, United Kingdom
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 233
- Registration Number
- NCT03557931
- Locations
- 🇺🇸
CNS Research Science, Inc., Jamaica, New York, United States
🇺🇸Synergy East, Lemon Grove, California, United States
🇺🇸Pacific Research Partners, LLC, Oakland, California, United States
Long-term Antipsychotic Pediatric Safety Trial
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Duke University
- Target Recruit Count
- 509
- Registration Number
- NCT03522168
- Locations
- 🇺🇸
UCLA Semel Institute, Los Angeles, California, United States
🇺🇸Beacon Medical Group, South Bend, Indiana, United States
🇺🇸Carolina Partners in Mental HealthCare, PLLC, Raleigh, North Carolina, United States
Chinese First Episode Schizophrenia's Optimal Dynamic Antipsychotic Treatment Regime
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 1260
- Registration Number
- NCT03510325
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Substance Misuse To Psychosis for Stimulants
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 240
- Registration Number
- NCT03485417
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Peking University
- Target Recruit Count
- 770
- Registration Number
- NCT03289026
- Locations
- 🇨🇳
Beijing Anding Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Shandong Mental Health Center, Jinan, Shandong, China
Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2023-12-20
- Target Recruit Count
- 316
- Registration Number
- NCT03198078
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, Oklahoma City, Oklahoma, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.